CGEM · Biotech · Nasdaq · As of 21 Nov 2026
Cullinan Therapeutics, Inc. stock: filings, catalysts and timeline
Sign in to follow
AIR Score
Cautious · 46 / 100
AIR confidence
Support behind the full AIR read.
What is this? →Hide
How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.
The Discovery Gap
High
Gap confidence
How fully AIR could measure this Gap — separate from the AIR Score's confidence.
What is this? →Hide
How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.
Five perspectives
FundamentalsWhat is this?HideToo few of the required measures on file
How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.
Source: SEC XBRL financial statements.
ValueWhat is this?HidePre-revenue — no valuation basis
How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.
Source: SEC XBRL financial statements and end-of-day prices.
News flowWhat is this?HideBalanced
What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.
Source: SEC EDGAR 8-K filings and FDA approvals.
MomentumWhat is this?HideWatch
The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.
Source: End-of-day prices.
SafetyWhat is this?HideBalanced
The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.
Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.
Rating words, not raw numbers.
Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on News flow, Momentum and Safety, and the missing score lowers its AIR confidence.
Discovery Gap: High (40/100) · Gap confidence 63/100
Discovery gap
Filings show more traction than the tape reflects.
Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.
What is this?Hide
How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.
Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.
How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.
This month at a glance
Evidence timeline
What changed — last 90 days
As of 12 Nov 2026The company reported Q3 2026 results with cash position of $313.8M providing runway into 2029.
Results · 8-K filed 10 Nov →
The company filed its quarterly report for the period ending September 30, 2026.
Quarterly/annual report · 10-Q filed 10 Nov →
What the company disclosed, not verified by AIR · sources link to the Evidence timeline below.
- Expected
Wed 10 Mar · expected 10-K
Last year filed 10 Mar 2026.
Fri 7 May · expected 10-Q
Last year filed 7 May 2026.
- Filed
Tue 10 Nov · 8-K
8-K · Item 2.02 — Results of operations
Cullinan reported Q3 2026 results with multiple clinical catalysts: CLN-978 multi-dose data in three autoimmune indications coming December; velinotamig initiated global Phase 1/2 study; CLN-049 potentially registrational Phase 2 in R/R AML underway; zipalertinib NDA submission initiated under FDA Real-Time Review. Cash position $313.8M provides runway into 2029.
Recognition: Balanced 49 → Balanced 45Gap High · 27 → Very high · 47Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
Tue 10 Nov · 10-Q
Quarterly report (10-Q), period ending 30 Sep 2026
Recognition: Balanced 49 → Balanced 45Gap High · 27 → Very high · 47Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
Mon 9 Nov · 8-K
8-K · Item 8.01 — Other events
Gap High · 27 → High · 36Progress is running ahead of attention.
Wed 4 Nov · 8-K
8-K · Item 8.01 — Other events
Recognition: Balanced 54 → Balanced 49Gap Medium · 17 → High · 27Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
Fri 2 Oct · 8-K
8-K · Item 8.01 — Other events
Gap Medium · 10 → Medium · 23Progress is running ahead of attention.
Thu 24 Sep · 8-K
8-K · Item 8.01 — Other events
Recognition: Balanced 61 → Balanced 50Market attention has faded.
The price trend weakened.
Mon 14 Sep · 8-K
Thu 13 Aug · 8-K
Thu 6 Aug · 8-K
Thu 6 Aug · 10-Q
Quarterly report (10-Q), period ending 30 Jun 2026
Tue 16 Jun · 8-K
Wed 10 Jun · 8-K
Mon 8 Jun · 8-K
Mon 18 May · 8-K
Thu 7 May · 8-K
Thu 7 May · 10-Q
Quarterly report (10-Q), period ending 31 Mar 2026
Tue 10 Mar · 8-K
Tue 10 Mar · 10-K
Annual report (10-K), FY2025
Thu 8 Jan · 8-K
Mon 8 Dec · 8-K
Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.
Ask AIR
What would change our view
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.